MRI Characterization of Mammographically Detected DCIS
| Status: | Recruiting |
|---|---|
| Healthy: | No |
| Age Range: | 18 - 80 |
| Updated: | 5/19/2018 |
| Start Date: | April 20, 2018 |
| End Date: | April 2032 |
| Contact: | Habib Rahbar |
| Email: | b-imaging-research@seattlecca.org |
| Phone: | 206-606-6777 |
MRI Characterization of Mammographically Detected Calcifications and Ductal Carcinoma in Situ
This is a single institution, prospective observational clinical trial for women with
mammographically detected suspicious calcifications who have been recommended breast biopsy.
The purpose of this study is to determine whether quantitative, multiparametric breast MRI
performed prior to biopsy can biologically characterize a common pre-invasive malignancy,
ductal carcinoma in situ (DCIS), which typically presents in asymptomatic women as suspicious
calcifications on mammography.
mammographically detected suspicious calcifications who have been recommended breast biopsy.
The purpose of this study is to determine whether quantitative, multiparametric breast MRI
performed prior to biopsy can biologically characterize a common pre-invasive malignancy,
ductal carcinoma in situ (DCIS), which typically presents in asymptomatic women as suspicious
calcifications on mammography.
The investigators will assess whether MRI signatures can determine which calcifications
identified as suspicious on mammography actually harbor DCIS, and whether these imaging
features correlate with pathologic markers of proliferation (Ki-67) and inflammation (cox-2)
within DCIS lesions.
The investigators will also explore whether quantitative MRI features in the peri-tumoral
region correlate with prognostic microenvironment markers of inflammation (TNFα) and
angiogenesis (VEGF). Finally, investigators will assess whether a multivariate model using
these markers can accurately predict risk of recurrence based on a multi-gene assay (Oncotype
DX DCIS score).
identified as suspicious on mammography actually harbor DCIS, and whether these imaging
features correlate with pathologic markers of proliferation (Ki-67) and inflammation (cox-2)
within DCIS lesions.
The investigators will also explore whether quantitative MRI features in the peri-tumoral
region correlate with prognostic microenvironment markers of inflammation (TNFα) and
angiogenesis (VEGF). Finally, investigators will assess whether a multivariate model using
these markers can accurately predict risk of recurrence based on a multi-gene assay (Oncotype
DX DCIS score).
Inclusion Criteria:
• Women aged 18 or older with suspicious calcifications identified on mammography without
an associated mass
Exclusion Criteria:
- Patients with prior history of breast cancer in the ipsilateral breast
- Patients with a newly diagnosed breast cancer in either breast
- Contra-indication to contrast-enhanced breast MRI (e.g. renal insufficiency with
GFR<60, contrast allergy, incompatible metal)
- Patients who currently are undergoing chemoprevention therapy (e.g. aromatase
inhibitors or selective estrogen receptor modulators)
- Women who are pregnant
We found this trial at
1
site
825 Eastlake Ave E
Seattle, Washington 98109
Seattle, Washington 98109
(206) 288-7222
Phone: 206-606-6714
Seattle Cancer Care Alliance Seattle Cancer Care Alliance (SCCA) is a cancer treatment center that...
Click here to add this to my saved trials
